Oramed Letter to Shareholders

Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023 Phase 2 NASH Trial Achieved Primary and Secondary Endpoints Definitive Deal Signed to Commercialize Oral Insulin in South Korea   $160 Million in Cash and Investments (as of September 30, 2022 ) NEW YORK , Dec.

Join our mailing list

Skip to content